Intellia’s most advanced in vivo candidates are Nex-z (formerly NTLA-2001) for the treatment of transthyretin amyloidosis (ATTR) and NTLA-2002 for the treatment of hereditary angioedema (HAE).

This transformative therapy would also be the first approved using in vivo CRISPR gene editing. Let's move on to nex-z in development for the treatment of ATTR amyloidosis. Starting with ATTR ...

Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.

Vivo has just unveiled the specs for its upcoming X200 Ultra smartphone, a device that was previously claimed to be able to ...

Vivo is expected to hold a major launch event in April in China. The event is likely to see the arrival of multiple devices, ...

The new phone, which costs just over $1,000, has a wide display and does not include Google's Android software.

vivo dropped a teaser over a week ago, which made us believe that the vivo T4x 5G could launch on February 20. Well, that didn't happen, and while vivo still hasn't announced the T4x 5G's launch ...

UPDATE: It seems like the Vivo X200 Ultra will not get a global model after all. “Vivo team member” confirmed that the report was fake, according to Abhishek Yadav. The phone will likely ...

STUNNING in Ancora Red and other eye-catching shades, the latest addition to vivo's V series has finally arrived in the ...

The Nothing Phone 3a Pro is a compelling device, but several alternatives offer similar or better features for the price. This article explores five phones, including OnePlus Nord 4 and Vivo V50, that ...

Instead, swing by NEX Atrium at level 1, and experience the sights, smells, and atmosphere of Isetan Singapore’s Sakura Matsuri Japanese food fair. Taking place till 23 Mar 2025, the lively mini food ...

Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD despite promising trials.